Overview

A Study of Niraparib as Single Agent in Participants With Advanced Solid Tumors

Status:
Completed
Trial end date:
2020-02-10
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of Niraparib in Japanese participants with advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Takeda
Treatments:
Niraparib